Federal IVF Cost Cuts and Access Expansion: Key Updates 2026

New federal actions aim to reduce IVF costs by 80% for medications like Gonal-f and Pergoveris via TrumpRx.gov starting 2026, alongside faster FDA approvals and employer fertility benefits to enhance accessibility.

---

Key Takeaways

IVF Medication Cost Cuts via TrumpRx.gov in 2026

A federal pricing agreement with EMD Serono will lower out-of-pocket costs for IVF drugs like Gonal-f and Pergoveris. Patients can access discounted medications directly through TrumpRx.gov starting January 2026, saving up to $3,000 per IVF cycle.

Faster FDA Approvals for Fertility Drugs

The FDA will fast-track approvals for fertility medications, including combination drugs like Pergoveris. This streamlining is expected to boost market competition and reduce medication costs by accelerating new treatment options to market.

Employer-Funded Fertility Benefits Now Voluntary

The U.S. government encourages employers to offer standalone fertility benefits akin to dental/vision coverage. This flexibility allows companies to design affordable plans without altering primary health insurance, improving employee access to IVF.

IVF Recognized as Essential Healthcare Policy

The White House policy shift classifies IVF as essential healthcare, not elective. This reclassification removes barriers in insurance coverage and employer-sponsored benefits, aligning with global health organizations’ recommendations.

Implementation Challenges in IVF Access Expansion

While TrumpRx.gov lowers medication costs, savings depend on manufacturer participation and patient eligibility. Experts stress that employer adoption of fertility benefits will determine how many families actually benefit from these policies.

---

Source: Read full article